{"id":"ambroxol","rwe":[],"tags":[{"label":"ambroxol","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Cytochrome P450 2D6","category":"target"},{"label":"CYP2D6","category":"gene"},{"label":"SLC6A4","category":"gene"},{"label":"GBA","category":"gene"},{"label":"R02AD05","category":"atc"},{"label":"Active","category":"status"},{"label":"Sore throat symptom","category":"indication"},{"label":"Expectorants","category":"pharmacology"},{"label":"Respiratory System Agents","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":275.224,"date":"","count":57,"signal":"Fractional exhaled nitric oxide increased","source":"DrugCentral FAERS","actionTaken":"Reported 57 times (LLR=275)"},{"llr":202.857,"date":"","count":57,"signal":"Myoglobin blood increased","source":"DrugCentral FAERS","actionTaken":"Reported 57 times (LLR=203)"},{"llr":182.287,"date":"","count":64,"signal":"Brain natriuretic peptide increased","source":"DrugCentral FAERS","actionTaken":"Reported 64 times (LLR=182)"},{"llr":177.418,"date":"","count":55,"signal":"Plantar fasciitis","source":"DrugCentral FAERS","actionTaken":"Reported 55 times (LLR=177)"},{"llr":172.384,"date":"","count":57,"signal":"Sensation of foreign body","source":"DrugCentral FAERS","actionTaken":"Reported 57 times (LLR=172)"},{"llr":150.037,"date":"","count":326,"signal":"Pneumonia","source":"DrugCentral FAERS","actionTaken":"Reported 326 times (LLR=150)"},{"llr":140.326,"date":"","count":123,"signal":"Interstitial lung disease","source":"DrugCentral FAERS","actionTaken":"Reported 123 times (LLR=140)"},{"llr":134.369,"date":"","count":73,"signal":"Pneumothorax","source":"DrugCentral FAERS","actionTaken":"Reported 73 times (LLR=134)"},{"llr":134.334,"date":"","count":99,"signal":"Hepatic function abnormal","source":"DrugCentral FAERS","actionTaken":"Reported 99 times (LLR=134)"},{"llr":123.093,"date":"","count":56,"signal":"Secretion discharge","source":"DrugCentral FAERS","actionTaken":"Reported 56 times (LLR=123)"},{"llr":117.578,"date":"","count":34,"signal":"Incision site pain","source":"DrugCentral FAERS","actionTaken":"Reported 34 times (LLR=118)"},{"llr":101.996,"date":"","count":71,"signal":"Lymphocyte count decreased","source":"DrugCentral FAERS","actionTaken":"Reported 71 times (LLR=102)"},{"llr":100.084,"date":"","count":61,"signal":"Obstructive airways disorder","source":"DrugCentral FAERS","actionTaken":"Reported 61 times (LLR=100)"},{"llr":94.505,"date":"","count":76,"signal":"Dysphonia","source":"DrugCentral FAERS","actionTaken":"Reported 76 times (LLR=95)"},{"llr":89.116,"date":"","count":52,"signal":"Macular degeneration","source":"DrugCentral FAERS","actionTaken":"Reported 52 times (LLR=89)"}],"commonSideEffects":[]},"trials":[],"aliases":[],"patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=AMBROXOL","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-19T23:28:05.348231+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-19T23:28:10.842753+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMBROXOL","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-19T23:28:11.144969+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL153479/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-19T23:28:11.855173+00:00"}},"allNames":"lasolvan","offLabel":[],"synonyms":["ambroxol hydrochloride","ambroxol","ambroxils","lasolvan","ambroxol HCl"],"timeline":[{"date":"1978-01-01","type":"positive","source":"DrugCentral","milestone":"YEAR INTRODUCED approval"}],"brandName":"Lasolvan","ecosystem":[{"indication":"Sore throat symptom","otherDrugs":[{"name":"benzocaine","slug":"benzocaine","company":""},{"name":"codeine","slug":"codeine","company":"Ani Pharms"},{"name":"dextromethorphan","slug":"dextromethorphan","company":"Ani Pharms"},{"name":"pheniramine","slug":"pheniramine","company":"Alcon"}],"globalPrevalence":null}],"mechanism":{"target":"Cytochrome P450 2D6","targets":[{"gene":"CYP2D6","source":"DrugCentral","target":"Cytochrome P450 2D6","protein":"Cytochrome P450 2D6"},{"gene":"SLC6A4","source":"DrugCentral","target":"Sodium-dependent serotonin transporter","protein":"Sodium-dependent serotonin transporter"},{"gene":"GBA","source":"DrugCentral","target":"Glucosylceramidase","protein":"Glucosylceramidase"},{"gene":"SCN10A","source":"DrugCentral","target":"Sodium channel protein type 10 subunit alpha","protein":"Sodium channel protein type 10 subunit alpha"}],"modality":"Small Molecule","drugClass":"ambroxol","explanation":"","oneSentence":"","technicalDetail":"Lasolvan exerts its effects by increasing the production of surfactant in the lungs, which is essential for maintaining proper lung function and facilitating the clearance of mucus."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/147","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=AMBROXOL","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=AMBROXOL","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T08:40:10.618079","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:28:13.506331+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"benzocaine","drugSlug":"benzocaine","fdaApproval":"","relationship":"same-class"},{"drugName":"lidocaine","drugSlug":"lidocaine","fdaApproval":"1948-11-19","patentExpiry":"May 10, 2031","patentStatus":"Patent protected","relationship":"same-class"},{"drugName":"dyclonine","drugSlug":"dyclonine","fdaApproval":"","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"}],"genericName":"ambroxol","indications":{"approved":[{"name":"Sore throat symptom","source":"DrugCentral","snomedId":267102003,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"benzocaine","brandName":"benzocaine","genericName":"benzocaine","approvalYear":"","relationship":"same-class"},{"drugId":"lidocaine","brandName":"lidocaine","genericName":"lidocaine","approvalYear":"1948","relationship":"same-class"},{"drugId":"dyclonine","brandName":"dyclonine","genericName":"dyclonine","approvalYear":"","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT07285369","phase":"NA","title":"High-Dose Ambroxol in Pediatric Type III Gaucher Disease (GD3)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Agyany Pharma LTD","startDate":"2025-03-01","conditions":["Gaucher Disease, Type 3"],"enrollment":12,"completionDate":"2027-01-01"},{"nctId":"NCT03843541","phase":"PHASE3","title":"A Clinical Trial to Compare the Efficacy and Safety of 1-week Treatment of Intravenous N-acetylcysteine (NAC) 600 mg Twice Daily, Ambroxol Hydrochloride 30 mg Twice Daily and Placebo as Expectorant Therapies in Adult Chinese Patients With Respiratory Tract Diseases and Abnormal Mucus Secretions","status":"COMPLETED","sponsor":"Zambon SpA","startDate":"2019-06-25","conditions":["Respiratory Tract Diseases","Abnormal Mucus Secretions"],"enrollment":333,"completionDate":"2021-02-05"},{"nctId":"NCT07149909","phase":"NA","title":"Fiberoptic Bronchoscopy in Severe Ventilator-associated Pneumonia","status":"COMPLETED","sponsor":"Benha University","startDate":"2023-12-15","conditions":["Ventilator-Associated Pneumonia","Severe Pneumonia","Critical Illness"],"enrollment":100,"completionDate":"2024-12-15"},{"nctId":"NCT06614894","phase":"PHASE2,PHASE3","title":"An Open Label Dose Escalation Study to Assess the Safety, Tolerability, and Pharmacologic Properties of High Dose Ambroxol Hydrochloride in Adult (≥ 18 Years of Age) Subjects With MPS III","status":"RECRUITING","sponsor":"Ozlem Goker-Alpan","startDate":"2024-12-01","conditions":["Sanfilippo Syndrome","MPS3"],"enrollment":10,"completionDate":"2026-06-30"},{"nctId":"NCT05287503","phase":"PHASE2","title":"Ambroxol as a Disease-modifying Treatment in GBA-PD","status":"COMPLETED","sponsor":"Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta","startDate":"2022-03-09","conditions":["Parkinson Disease","GBA Gene Mutation"],"enrollment":65,"completionDate":"2024-12-20"},{"nctId":"NCT05778617","phase":"PHASE3","title":"Ambroxol to Slow Progression in Parkinson Disease","status":"RECRUITING","sponsor":"University College, London","startDate":"2025-02-25","conditions":["Parkinson Disease"],"enrollment":330,"completionDate":"2029-09"},{"nctId":"NCT06693362","phase":"PHASE1","title":"A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of Uterine Blood Mesenchymal Stem Cells Injection for the Treatment of Severe Pneumonia Caused by Viruses","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2025-01-20","conditions":["Severe Viral Pneumonia(Not Include COVID-19)"],"enrollment":60,"completionDate":"2028-06-30"},{"nctId":"NCT02914366","phase":"PHASE2","title":"Ambroxol as a Treatment for Parkinson's Disease Dementia","status":"UNKNOWN","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2015-11","conditions":["Parkinson's Disease Dementia"],"enrollment":55,"completionDate":"2025-12"},{"nctId":"NCT06193421","phase":"PHASE1,PHASE2","title":"High-Dose Ambroxol in GBA1-Related Parkinson","status":"UNKNOWN","sponsor":"Agyany Pharma LTD","startDate":"2023-10-24","conditions":["Parkinson Disease","GBA Gene Mutation"],"enrollment":40,"completionDate":"2025-04-30"},{"nctId":"NCT05663905","phase":"PHASE4","title":"Efficacy of Intravenous Amboxol Hydrochloride as an Adjunct Therapy for Severe Pneumonia in Critically Ill Patients","status":"COMPLETED","sponsor":"National University of Malaysia","startDate":"2023-01-07","conditions":["Severe Pneumonia","Community-acquired Pneumonia","Hospital-acquired Pneumonia","Critical Illness"],"enrollment":32,"completionDate":"2023-10-31"},{"nctId":"NCT04588285","phase":"PHASE2","title":"Ambroxol in New and Early DLB, A Phase IIa Multicentre Randomized Controlled Double Blind Clinical Trial","status":"UNKNOWN","sponsor":"Helse Fonna","startDate":"2021-05-04","conditions":["Dementia With Lewy Bodies"],"enrollment":180,"completionDate":"2025-07-01"},{"nctId":"NCT04405596","phase":"PHASE1,PHASE2","title":"Ambroxol as a Novel Disease Modifying Treatment for Lewy Body Dementia","status":"NOT_YET_RECRUITING","sponsor":"London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's","startDate":"2025-01","conditions":["Lewy Body Disease"],"enrollment":15,"completionDate":"2027-01"},{"nctId":"NCT05959850","phase":"PHASE2","title":"A Double-blind Randomised, Placebo-controlled Clinical Trial to Test Ambroxol Treatment in ALS","status":"UNKNOWN","sponsor":"The Florey Institute of Neuroscience and Mental Health","startDate":"2023-06-13","conditions":["Amyotrophic Lateral Sclerosis"],"enrollment":50,"completionDate":"2024-12"},{"nctId":"NCT05830396","phase":"PHASE2,PHASE3","title":"GRoningen Early-PD Ambroxol Treatment","status":"UNKNOWN","sponsor":"University Medical Center Groningen","startDate":"2023-05","conditions":["Parkinson","Parkinson Disease"],"enrollment":80,"completionDate":"2025-07"},{"nctId":"NCT05773443","phase":"","title":"ANeED Joint Effort 21: eHealth and a PPI Program in Dementia With Lewybodies (DLB)","status":"RECRUITING","sponsor":"University of Bergen","startDate":"2023-03","conditions":["Dementia, Lewy Body"],"enrollment":100,"completionDate":"2026-12"},{"nctId":"NCT03950050","phase":"PHASE2","title":"Ambroxol Therapy for Patients With Type 1 Gaucher Disease and Suboptimal Response to Enzyme Replacement Therapy","status":"COMPLETED","sponsor":"Shaare Zedek Medical Center","startDate":"2019-03-01","conditions":["Gaucher Disease, Type 1"],"enrollment":40,"completionDate":"2022-12-30"},{"nctId":"NCT04388969","phase":"","title":"World Data on Ambroxol for Patients With GD and GBA Related PD","status":"UNKNOWN","sponsor":"Shaare Zedek Medical Center","startDate":"2020-05-06","conditions":["Gaucher Disease","Parkinson Disease","GBA Gene Mutation"],"enrollment":300,"completionDate":"2024-01-31"},{"nctId":"NCT05558878","phase":"NA","title":"Effect of Ambroxol in Diabetic Peripheral Neuropathy","status":"UNKNOWN","sponsor":"Ain Shams University","startDate":"2022-10-01","conditions":["Diabetic Neuropathy Peripheral"],"enrollment":80,"completionDate":"2023-11"},{"nctId":"NCT03583658","phase":"PHASE3","title":"Efficacy and Safety Study of New Ambroxol Hardboiled Lozenges in Acute Pharyngitis","status":"COMPLETED","sponsor":"Sanofi","startDate":"2018-06-30","conditions":["Pharyngitis"],"enrollment":390,"completionDate":"2018-09-02"},{"nctId":"NCT05002192","phase":"","title":"A Retrospective, Real-world Study of ELP Used in the Expectorant Treatment of Community-acquired Pneumonia","status":"UNKNOWN","sponsor":"Beijing Grand Johamu Pharmaceutical Company, Ltd.","startDate":"2020-09-01","conditions":["Community-acquired Pneumonia"],"enrollment":10000,"completionDate":"2022-12-31"},{"nctId":"NCT02941822","phase":"PHASE2","title":"Ambroxol in Disease Modification in Parkinson Disease","status":"COMPLETED","sponsor":"University College, London","startDate":"2016-12","conditions":["Parkinson Disease"],"enrollment":23,"completionDate":"2018-05"},{"nctId":"NCT03177889","phase":"NA","title":"Lung Dispersing, Turbid Descending and Gut Clearing Decoction for Bronchiectasis","status":"UNKNOWN","sponsor":"Guangzhou Institute of Respiratory Disease","startDate":"2021-12-31","conditions":["Bronchiectasis Adult","Traditional Chinese Medicine","Quality of Life","Exacerbation"],"enrollment":80,"completionDate":"2023-12-31"},{"nctId":"NCT00525044","phase":"PHASE3","title":"Double-blind Trial to Investigate Efficacy and Tolerance of Ambroxol Lozenges 20 mg in Sore Throat","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2007-08-01","conditions":["Pharyngitis"],"enrollment":249,"completionDate":"2008-01-01"},{"nctId":"NCT03415269","phase":"PHASE2","title":"A Study of the Effect of 20 mg Ambroxol Hydrochloride on Acute Cough.","status":"COMPLETED","sponsor":"Hull University Teaching Hospitals NHS Trust","startDate":"2018-02-15","conditions":["Cough"],"enrollment":14,"completionDate":"2018-04-19"},{"nctId":"NCT00148499","phase":"PHASE3","title":"Efficacy and Tolerability of Ambroxol Lozenge 20 mf in Relieving Pain of Sore Throat in Pat. With Acute/Viralpharyngitis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-10","conditions":["Pharyngitis"],"enrollment":751,"completionDate":"2006-06"},{"nctId":"NCT02792946","phase":"PHASE3","title":"Compare the Efficacy and Safety of Surfolase CR Tablet With Surfolase Capsule in Patients With Acute Bronchitis","status":"COMPLETED","sponsor":"Hyundai Pharmaceutical Co., LTD.","startDate":"2015-11","conditions":["Acute Bronchitis"],"enrollment":244,"completionDate":"2016-01"},{"nctId":"NCT01713179","phase":"PHASE1,PHASE2","title":"Effects of Oral Mucolytics on Tear Film and Ocular Surface","status":"COMPLETED","sponsor":"Hallym University Kangnam Sacred Heart Hospital","startDate":"2011-08","conditions":["In the Present Study, we Investigated the Effects of Oral Ambroxol on Tear Film and Ocular Surface."],"enrollment":20,"completionDate":"2011-10"},{"nctId":"NCT02572609","phase":"PHASE1","title":"Relative Bioavailability Study Between Two Formulations Containing Ambroxol Hydrochloride","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-11","conditions":["Healthy"],"enrollment":0,"completionDate":"2011-12"},{"nctId":"NCT02036775","phase":"PHASE1","title":"Pharmacokinetics and Bioavailability Study of Lasolvan Hard Capsules and Effervescent Tablets in Healthy Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2014-03","conditions":["Healthy"],"enrollment":24,"completionDate":"2014-05"},{"nctId":"NCT02395913","phase":"PHASE1","title":"Compare Safety and Pharmacokinetic Properties of Surfolase Capsule(Acebrophylline 100mg) and Surfolase CR(200mg)","status":"COMPLETED","sponsor":"Hyundai Pharmaceutical Co., LTD.","startDate":"2013-07","conditions":["Healthy Male"],"enrollment":72,"completionDate":"2013-09"},{"nctId":"NCT02373891","phase":"PHASE1","title":"Study to Evaluate the Effect of Food on the Pharmacokinetics of Surfolase CR Tablet in Healthy Volunteers","status":"COMPLETED","sponsor":"Hyundai Pharmaceutical Co., LTD.","startDate":"2014-04","conditions":["Healthy Volunteers"],"enrollment":25,"completionDate":"2014-07"},{"nctId":"NCT02194283","phase":"PHASE1","title":"Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of Ambroxol Lozenges in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2009-10","conditions":["Healthy"],"enrollment":34,"completionDate":""},{"nctId":"NCT02194270","phase":"PHASE1","title":"Relative Bioavailability of Ambroxol Hydrochloride of Soft Pastilles Compared to Ambroxol Hydrochloride Syrup in Healthy Male and Female Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2004-09","conditions":["Healthy"],"enrollment":24,"completionDate":""},{"nctId":"NCT02194257","phase":"PHASE1","title":"Investigation of the Metabolism and Pharmacokinetics of Ambroxol in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2008-10","conditions":["Healthy"],"enrollment":12,"completionDate":""},{"nctId":"NCT02194296","phase":"PHASE1","title":"Relative Bioavailability of Ambroxol Hydrochloride Lozenge in Comparison to Ambroxol Hydrochloride Syrup (Mucosolvan®) in Healthy Female and Male Volunteers","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"1999-06","conditions":["Healthy"],"enrollment":20,"completionDate":""},{"nctId":"NCT01361802","phase":"PHASE2","title":"Ambroxol Spray Sore Throat Study","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2011-05","conditions":["Pharyngitis","Pain"],"enrollment":494,"completionDate":""},{"nctId":"NCT00144274","phase":"PHASE3","title":"Ambroxol Lozenges 20mg in Relieving the Pain of Sore Throat in Adolescent Patients With Acute Viral Pharyngitis","status":"COMPLETED","sponsor":"Boehringer Ingelheim","startDate":"2005-04","conditions":["Pharyngitis"],"enrollment":220,"completionDate":"2005-11"},{"nctId":"NCT01463215","phase":"PHASE1,PHASE2","title":"Clinical Trial of Ambroxol in Patients With Type I Gaucher Disease","status":"SUSPENDED","sponsor":"Exsar Corporation","startDate":"2012-12","conditions":["Type I Gaucher Disease"],"enrollment":20,"completionDate":"2015-08"},{"nctId":"NCT01573663","phase":"PHASE1","title":"A Drug-Drug Interaction Study of Ambroxol and Levodropropizine","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2012-02","conditions":["Healthy"],"enrollment":21,"completionDate":"2012-04"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"NDDF":"004176","UNII":"200168S0CL","CHEBI":"CHEBI:31198","INN_ID":"3692","RXNORM":"438399","UMLSCUI":"C0002421","chemblId":"CHEMBL153479","ChEMBL_ID":"CHEMBL153479","KEGG_DRUG":"D01479","DRUGBANK_ID":"DB06742","PUBCHEM_CID":"2132","SNOMEDCT_US":"698024002","IUPHAR_LIGAND_ID":"10692","SECONDARY_CAS_RN":"23828-92-4","MESH_DESCRIPTOR_UI":"D000551"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"pharmacokinetics":{"source":"DrugCentral","bioavailability":"77%"},"publicationCount":970,"therapeuticAreas":["Respiratory"],"atcClassification":{"source":"DrugCentral","atcCode":"R02AD05","allCodes":["R02AD05","R03CC63","R05CB06"]},"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-19T23:28:13.506331+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}